How to Get Vyvanse in Colorado

What Vyvanse Is and Why Access Rules Matter in Colorado

Vyvanse (lisdexamfetamine dimesylate) is a prodrug stimulant that the body converts to dextroamphetamine after oral ingestion. The FDA approved it for ADHD in 2007 and for moderate-to-severe binge eating disorder (BED) in adults in 2015 [1]. Because lisdexamfetamine is a Schedule II controlled substance under federal law, Colorado imposes specific prescribing, dispensing, and monitoring rules that differ from those for non-controlled medications [2].

Colorado's Prescription Drug Monitoring Program (PDMP), operated through the Colorado Board of Pharmacy, requires prescribers to query the PDMP before writing a new Schedule II prescription and at least annually thereafter [3]. A 2022 analysis in JAMA Network Open found that state PDMP mandates reduced stimulant prescription fills by 7.2% in the first year of implementation without reducing fills among patients with documented ADHD diagnoses [4]. This means legitimate patients retain access while the system flags potential diversion.

Schedule II drugs cannot carry refills under federal law. Each 30-day supply requires a new prescription, though Colorado permits prescribers to issue up to three sequential 30-day prescriptions (a 90-day supply) on a single visit, with future fill dates written on each script [5].

Who Can Prescribe Vyvanse in Colorado

Any Colorado-licensed prescriber with an active DEA registration and Schedule II authority can write a Vyvanse prescription. That includes MDs, DOs, nurse practitioners with prescriptive authority granted under the Colorado Nurse Practice Act, and physician assistants [6]. Colorado removed the previous requirement for NP collaborative agreements in 2022, giving NPs full practice authority after 3 to 600 hours of supervised practice [7].

A prescriber must hold a Colorado medical license or be registered through an interstate compact that Colorado recognizes. The Psychology Interjurisdictional Compact (PSYPACT) does not grant prescriptive authority for controlled substances, so psychologists who diagnose ADHD in Colorado cannot write the Vyvanse prescription themselves [8].

For pediatric patients, the American Academy of Pediatrics recommends behavioral therapy as first-line treatment for children aged 4 to 5, while stimulant medication is first-line for children 6 and older [9]. Wigal et al. (2017) demonstrated that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV scores compared to placebo in children aged 6 to 12 (effect size d = 0.80, P<0.001) [10].

Telehealth Prescribing Rules for Vyvanse in Colorado

Colorado permits telehealth prescribing of Schedule II controlled substances, provided the visit uses synchronous audio-video technology. Audio-only visits are not sufficient for an initial controlled substance prescription under Colorado's Ryan Haight Act compliance framework [11]. The DEA's post-pandemic telemedicine rule (finalized in late 2025) requires that prescribers either conduct an in-person evaluation or use a DEA-registered telemedicine platform for initial Schedule II prescriptions [12].

In practice, many Colorado telehealth ADHD clinics operate under a hybrid model: the initial evaluation occurs via video, and the prescriber verifies the patient's identity and Colorado residency during the visit. The Colorado Medical Board has stated that the standard of care for a telehealth visit must match that of an in-person visit, including documentation of a structured ADHD assessment [13].

Patients seeking telehealth ADHD care should confirm that the provider holds a Colorado license, has an active DEA registration, and can prescribe Schedule II substances. Some national telehealth platforms use prescribers licensed in multiple states but may not hold Colorado-specific DEA registrations, which would prevent them from dispensing to Colorado pharmacies.

A 2023 study published in JAMA Psychiatry found that telehealth ADHD evaluations produced diagnostic agreement rates of 92% compared with in-person assessments when structured instruments were used [14]. This supports the clinical validity of remote ADHD evaluation for Colorado patients who lack access to in-person specialists, particularly in rural counties.

What Labs and Documentation Are Needed Before Starting Vyvanse

Vyvanse does not require routine laboratory testing before initiation in most adults, though clinical guidelines recommend a baseline evaluation that includes blood pressure, heart rate, height, and weight [15]. The American Heart Association's 2008 scientific statement recommends a focused cardiac history and physical exam before starting stimulant therapy. Routine ECGs are not recommended for patients without cardiac symptoms or family history of sudden death [16].

For patients with pre-existing cardiovascular conditions, the prescriber may order a baseline ECG and refer to cardiology. A meta-analysis by Westover and Halm (2012) in the American Journal of Psychiatry, covering 2.3 million patient-years, found no statistically significant increase in serious cardiovascular events among adults using stimulant medications (RR 0.83 to 95% CI 0.72 to 0.96) [17].

Documentation requirements for a Vyvanse prescription typically include a formal ADHD diagnosis using DSM-5 criteria, with symptom onset before age 12, evidence of functional impairment in two or more settings, and exclusion of alternative diagnoses. Colorado prescribers must document this assessment in the medical record and query the PDMP before prescribing [3].

For binge eating disorder, the prescriber should document at least one episode per week for three months, per DSM-5 criteria, along with marked distress. The PDMP query is required regardless of indication [18].

Prior Authorization and Insurance Coverage in Colorado

Colorado Medicaid (Health First Colorado) does not cover Vyvanse for ADHD or binge eating disorder indications. Coverage through Medicaid is limited to type 2 diabetes indications, which do not apply to lisdexamfetamine [19]. This means Medicaid patients in Colorado must either use an alternative covered stimulant (such as generic mixed amphetamine salts or methylphenidate) or pay out of pocket.

Commercial insurers in Colorado commonly require prior authorization for brand-name Vyvanse. The typical PA process involves the prescriber submitting documentation of the diagnosis, prior medication trials, and clinical rationale. Many Colorado commercial plans follow a step-therapy protocol that requires failure of at least one generic stimulant (usually generic Adderall or methylphenidate) before approving lisdexamfetamine [20].

Since the FDA authorized generic lisdexamfetamine in August 2023, several manufacturers (including Alvogen and Sandoz) have entered the market [21]. Generic versions may face fewer PA hurdles than brand-name Vyvanse. Patients should ask their pharmacy to run both the brand and generic through insurance to compare copays.

For patients denied coverage, Takeda offers the Vyvanse Patient Assistance Program for qualifying uninsured or underinsured individuals. Eligibility generally requires household income below 250% of the federal poverty level [22].

How to Fill a Vyvanse Prescription at Colorado Pharmacies

Any licensed retail pharmacy in Colorado can dispense Vyvanse or generic lisdexamfetamine. Schedule II prescriptions in Colorado may be transmitted electronically via Electronic Prescribing for Controlled Substances (EPCS), which most major pharmacy chains now support [23]. Paper prescriptions and verbal (call-in) prescriptions for Schedule II substances are also permitted under Colorado law, though federal rules prohibit faxed Schedule II prescriptions except in specific hospice or long-term care scenarios.

Colorado has 64 counties, and rural areas may have limited pharmacy access. The Health Resources and Services Administration (HRSA) designates 33 Colorado counties as mental health professional shortage areas [24]. Patients in these regions may benefit from mail-order pharmacies, though Schedule II mail-order dispensing must comply with DEA regulations for controlled substance shipping.

Licensed 503A compounding pharmacies in Colorado can compound lisdexamfetamine preparations when a patient has a specific clinical need that commercially available dosage forms do not meet, such as a dye allergy or difficulty swallowing capsules. The pharmacy must hold a valid Colorado Board of Pharmacy compounding license and comply with USP 795 standards [25].

Patients transferring an existing Vyvanse prescription from another state to Colorado should be aware that Schedule II prescriptions cannot be transferred between pharmacies under federal law. The patient will need a new prescription from a Colorado-licensed prescriber or from an out-of-state prescriber who holds a Colorado-valid license [5].

Dosing, Titration, and Ongoing Monitoring

The FDA label recommends starting lisdexamfetamine at 30 mg once daily in the morning for both ADHD and BED, with titration in 10 mg or 20 mg increments at weekly intervals [1]. The maximum approved dose is 70 mg daily. A phase III trial in adults with ADHD demonstrated that 70 mg/day produced a mean ADHD-RS-IV reduction of 18.6 points versus 8.2 points for placebo (P<0.001, N = 414) [10].

For binge eating disorder, the key trial (N = 724) showed that lisdexamfetamine 50 mg and 70 mg reduced binge days per week from a baseline of 4.51 to 0.97 and 0.90, respectively, compared with 2.26 for placebo at 12 weeks [26]. The effect was durable through 38 weeks of open-label extension.

Colorado prescribers should schedule follow-up visits every 30 days during titration and at least every 90 days once a stable dose is reached. Each follow-up should include blood pressure, heart rate, weight assessment, and a PDMP query [3]. Growth monitoring is required for pediatric patients, as stimulants may suppress appetite and slow height velocity. A longitudinal study by Faraone et al. (2008) found a mean height deficit of approximately 1 cm per year during the first three years of stimulant treatment, which attenuated after discontinuation [27].

Common adverse effects include decreased appetite (reported in 27% of adult ADHD patients), dry mouth (26%), and insomnia (19%) [1]. The prodrug mechanism of lisdexamfetamine provides a smoother pharmacokinetic curve compared with immediate-release dextroamphetamine, with peak plasma concentrations occurring approximately 3.5 hours post-dose [28].

Cost Comparison: Brand Vyvanse vs. Generic Lisdexamfetamine in Colorado

Brand-name Vyvanse carries an average retail price between $350 and $450 for a 30-day supply at Colorado pharmacies. Generic lisdexamfetamine typically costs between $30 and $100 depending on the manufacturer and pharmacy, representing a 75% to 90% reduction [21].

Colorado patients with commercial insurance will generally pay a Tier 2 or Tier 3 copay for generic lisdexamfetamine and a Tier 4 or specialty copay for brand Vyvanse. Self-pay patients should compare prices across pharmacies using pricing transparency tools, as independent pharmacies occasionally undercut chain pricing on generics.

Patients enrolled in Colorado's CHP+ (Child Health Plan Plus) program should verify formulary status, as CHP+ maintains a separate formulary from Medicaid. Some CHP+ plans cover generic lisdexamfetamine for pediatric ADHD with step therapy [29].

The 340B Drug Pricing Program allows qualifying Federally Qualified Health Centers (FQHCs) in Colorado to purchase lisdexamfetamine at significantly reduced rates. Colorado has 23 FQHC organizations operating over 230 delivery sites, and eligible patients receiving care at these centers may access lower-cost prescriptions [30].